Lipoamino acid-modified GnRH analogs with receptor-mediated antiproliferative activity in prostate and ovarian cancer cells

[1]  P. Limonta,et al.  Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions , 2020, International journal of molecular sciences.

[2]  K. Koo,et al.  Current Status and Future Perspectives of Checkpoint Inhibitor Immunotherapy for Prostate Cancer: A Comprehensive Review , 2020, International journal of molecular sciences.

[3]  H. Van Poppel,et al.  Considerations for the use of gonadotropin‐releasing hormone agonists and antagonists in patients with prostate cancer , 2020, International journal of urology : official journal of the Japanese Urological Association.

[4]  F. Saad,et al.  Emerging therapeutic targets for patients with advanced prostate cancer. , 2019, Cancer treatment reviews.

[5]  M. Hudson.  Human , 2018, Critical Theory and the Classical World.

[6]  A. Oza,et al.  ZoptEC: Phase III randomized controlled study comparing zoptarelin with doxorubicin as second line therapy for locally advanced, recurrent, or metastatic endometrial cancer (NCT01767155). , 2018 .

[7]  G. Emons,et al.  The Role of Gonadotropin-Releasing Hormone in Cancer Cell Proliferation and Metastasis , 2017, Front. Endocrinol..

[8]  I. Toth,et al.  New gonadotropin-releasing hormone glycolipids with direct antiproliferative activity and gonadotropin-releasing potency. , 2017, International journal of pharmaceutics.

[9]  T. Minko,et al.  LHRH-Targeted Drug Delivery Systems for Cancer Therapy. , 2017, Mini reviews in medicinal chemistry.

[10]  J. George,et al.  Physiology of Gnrh and Gonadotropin Secretion , 2015 .

[11]  I. Toth,et al.  Evaluation of the Biological Properties and the Enzymatic Stability of Glycosylated Luteinizing Hormone-Releasing Hormone Analogs , 2015, The AAPS Journal.

[12]  M. Borad,et al.  Novel LHRH-receptor-targeted cytolytic peptide, EP-100: first-in-human phase I study in patients with advanced LHRH-receptor-expressing solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[13]  M. Beckmann,et al.  Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors , 2014, International Journal of Gynecologic Cancer.

[14]  G. Sonpavde,et al.  The hypothalamic–pituitary–gonadal axis and prostate cancer: implications for androgen deprivation therapy , 2014, World Journal of Urology.

[15]  I. Toth,et al.  Synthesis and in vitro evaluation of glycosyl derivatives of luteinizing hormone-releasing hormone (LHRH). , 2013, Bioorganic & medicinal chemistry.

[16]  A. Schally,et al.  Chapter 73 – LHRH Analogs , 2013 .

[17]  I. Toth,et al.  Lipidated analogues of luteinizing hormone-releasing hormone (LHRH) reduce serum levels of follicle-stimulating hormone (FSH) after oral administration. , 2012, International journal of pharmaceutics.

[18]  Qiong-yan Lin,et al.  Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice , 2012, Journal of Zhejiang University SCIENCE B.

[19]  R. Rink,et al.  To protect peptide pharmaceuticals against peptidases. , 2010, Journal of pharmacological and toxicological methods.

[20]  G. Mező,et al.  Receptor-mediated tumor targeting based on peptide hormones , 2010, Expert opinion on drug delivery.

[21]  S. Ferracuti,et al.  GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors , 2009, Endocrine.

[22]  A. Navratil,et al.  Effects of Gonadotrophin‐Releasing Hormone Outside the Hypothalamic‐Pituitary‐Reproductive Axis , 2009, Journal of neuroendocrinology.

[23]  D. Harrison,et al.  Gonadotropin-releasing hormone receptor levels and cell context affect tumor cell responses to agonist in vitro and in vivo. , 2008, Cancer research.

[24]  M. Tesone,et al.  Regulation of ovarian angiogenesis and apoptosis by GnRH‐I analogs , 2008, Molecular reproduction and development.

[25]  P. Leung,et al.  Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion , 2007, Endocrine.

[26]  P. Limonta,et al.  Gonadotropin-releasing hormone agonists reduce the migratory and the invasive behavior of androgen-independent prostate cancer cells by interfering with the activity of IGF-I. , 2007, International journal of oncology.

[27]  S. Dharap,et al.  Tumor-specific targeting of an anticancer drug delivery system by LHRH peptide. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[28]  G. Emons,et al.  Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer , 2003, Reproductive biology and endocrinology : RB&E.

[29]  C. Leuschner,et al.  Human prostate cancer cells and xenografts are targeted and destroyed through luteinizing hormone releasing hormone receptors , 2003, The Prostate.

[30]  R. Millar,et al.  Conformational constraint of mammalian, chicken, and salmon GnRHs, but not GnRH II, enhances binding at mammalian and nonmammalian receptors: evidence for preconfiguration of GnRH II. , 2002, Molecular endocrinology.

[31]  G. Kéri,et al.  Relationship between lipophilicity and antitumor activity of molecule library of Mannich ketones determined by high-performance liquid chromatography, clogP calculation and cytotoxicity test. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[32]  C. McArdle,et al.  Signaling and antiproliferative effects mediated by GnRH receptors after expression in breast cancer cells using recombinant adenovirus. , 2001, Endocrinology.

[33]  P. Leung,et al.  Estradiol Regulates Gonadotropin-Releasing Hormone (GnRH) and its Receptor Gene Expression and Antagonizes the Growth Inhibitory Effects of GnRH in Human Ovarian Surface Epithelial and Ovarian Cancer Cells**This work was supported by grants from Medical Research Council of Canada. , 2001, Endocrinology.

[34]  G. Emons,et al.  Luteinizing hormone-releasing hormone agonist triptorelin and antagonist cetrorelix inhibit EGF-induced c-fos expression in human gynecological cancers. , 2000, Gynecologic oncology.

[35]  A. Schally,et al.  Cancer chemotherapy based on targeting of cytotoxic peptide conjugates to their receptors on tumors. , 1999, European journal of endocrinology.

[36]  S. Kakar,et al.  Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues. , 1995, Cancer letters.

[37]  P. Artursson,et al.  Lipidic conjugates of luteinizing hormone releasing hormone (LHRH)+ and thyrotropin releasing hormone (TRH)+ that release and protect the native hormones in homogenates of human intestinal epithelial (Caco-2) cells , 1994 .

[38]  I. Toth.  A novel chemical approach to drug delivery: lipidic amino acid conjugates. , 1994, Journal of drug targeting.

[39]  H. Fraser.  LHRH analogues: their clinical physiology and delivery systems. , 1988, Bailliere's clinical obstetrics and gynaecology.

[40]  K. Höffken.  LH-RH Agonists in Oncology , 1988, Springer Berlin Heidelberg.

[41]  V. Mahesh.  Regulation of Ovarian and Testicular Function , 1987, Advances in Experimental Medicine and Biology.

[42]  K. Eidne,et al.  Gonadotropin-releasing hormone (GnRH)-binding sites in human breast cancer cell lines and inhibitory effects of GnRH antagonists. , 1987, The Journal of clinical endocrinology and metabolism.

[43]  J. J. Nestor,et al.  LHRH and its analogs : contraceptive and therapeutic applications , 1984 .